F&P: Mask sales have remained strong

AUCKLAND, New Zealand – Fisher & Paykel Healthcare expects full year operating revenue for the 2023 financial year to be within the range of about $1.55 billion to $1.6 billion, the company announced on Jan. 19. 

In F&P’s Homecare Product Group, sales of obstructive sleep apnea masks have remained strong, said Lewis Gradon, managing director and CEO. 

“Our mask sales growth rate is currently tracking above that of our first half as global supply of CPAP hardware improves and our Evora Full continues to perform well,” he said. 

In the Hospital Hardware Group, revenue continues to exceed pre-pandemic levels, as F&P responds to various COVID-19 surges, including in China, Gradon said. 

“For the second half of this financial year, we currently estimate the relative proportion of our Hospital sales between hardware and consumables will be similar to the first half,” he said. 

F&P doesn’t expect any material impact on its full year constant currency operating expense growth target that it guided to in November. 

• Read how F&P’s Homecare Product Group was a bright spot in the company’s financial results for the first half of the 2023 financial year, with revenue up 10% over the prior comparable period.